Our results suggest that activation of TGR5 by INT-777 ameliorates STZ-induced cognitive impairment by modulating apoptosis, neurogenesis, and neuronal firing, which might provide new insight into the mechanism of AD and highlight TGR5 as a novel and promising target for the prevention or treatment of AD. The gene discussed is GPBAR1; the disease is Cognitive impairment.